[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Rune Skovgaard Rasmussen\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":135},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,48,76,103],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100632333","phase-2-effect-of-testosterone-on-elderly-frail-men-with-testosterone-deficiency-100632333",false,"NCT07512323","Effect of Testosterone on Elderly Frail Men With Testosterone Deficiency","Effect of Testosterone on Elderly Frail Men With Testosterone Deficiency - a Double-blinded, Randomized and Placebo-controlled Intervention Study","Inclusion Criteria:\n\n* Men aged 70 or over.\n* Living at home in their own home or in sheltered housing.\n* Independent walking function, possibly with a walking aid.\n* Able to perform the chair-stand test a maximum of 8 times in 30 seconds or Timed Up and Go (TUG) of at least 30 seconds.\n* There must be at least 3 symptoms of frailty or objective findings.\n* Serum testosterone \\\u003C 10 nmol\u002FL as an average of 2 independent measurements at the Center for Growth and Reproduction, Rigshospitalet.\n\nExclusion Criteria:\n\n* Known or previous prostate cancer.\n* Abnormally elevated serum PSA (PSA = prostate-specific antigen) corresponding to PSA \\> 5 ng\u002Fml or PSA \\> 0.15 ng\u002Fml\u002Fcc (relative to prostate size in cubic centimeters (cc)).\n* Hemochromatosis.\n* Heart diseases in the form of: Peri-, myo-, or endocarditis, angina pectoris, severe heart failure (NYHA class III and IV), severe hypertension (systolic BP \\> 180 or diastolic BP \\> 105 mmHg after possible antihypertensive treatment). - Resting dyspnea.\n* Liver (ASAT \\> 2 x upper normal limit) or renal insufficiency (serum creatinine \\> 200 micromol\u002Fl).\n* Severe intractable epilepsy or migraine.\n* Insulin treatment.\n* Previous or current bisphosphonate, fluoride, HRT, SERM, strontium, teriparatide, or more than 3 weeks of prednisolone treatment.\n* Joint disease with acute inflammation.\n* Active cancer disease, in chemo- or radiotherapy.\n* Bone metabolic disease except for age-related osteoporosis.\n* Autoimmune diseases, chronic systemic diseases (cirrhosis, AIDS, chronic renal failure).\n* Primary testosterone deficiency in the form of testicular dysgenesis, Klinefelter syndrome (47,XXY), 46,XX males, LH resistance, Y chromosome deletions, other sex chromosome abnormalities.\n* Significant abuse, mental illness, dementia, physical handicaps with inability to complete the intervention or tests, or to give informed consent.\n* Contraindications for testosterone undecanoate are thus included in exclusion criteria, such as the presence of liver tumors, breast carcinoma, and prostate cancer, for which trial participants will be examined before the start of the trial.","MALE","70 Years",{"count":19,"type":20},96,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","The purpose of this study is to increase the functional level of the elderly to thereby reduce fall risk, improve motor skills, and increase psychological well-being, as well as to assess whether the restoration of a normal testosterone level contributes to a faster recovery. The effect of testosterone is investigated as measured by physical and mental functional capacity, including cognition, in hypogonadal elderly men with a significant loss of function. The study is aimed at participants who are too weak to participate in the progressive strength training.",[26,27,28,29],"Frail Elderly Patients","Hypogonadal Males","Testosterone Replacement Therapy","Falls (Accidents) in Old Age",[31,32,33,34],"hypogonadism","frailty","falls","testosterone replacement therapy","NOT_YET_RECRUITING","2026-04-29",{"date":38,"type":39},"2026-05-06","ACTUAL",{"date":41,"type":20},"2026-08-01",{"date":43,"type":20},"2030-09-30",{"name":45,"class":46},"Rune Skovgaard Rasmussen","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":55,"minAge":4,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":21,"phases":58,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":4},"100603340","phase-2-improved-treatment-and-monitoring-of-alzheimers-disease-100603340","NCT07135245","Improved Treatment and Monitoring of Alzheimer's Disease","Improved Treatment and Monitoring of Alzheimer's Disease - a Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n* Decreased cognitive abilities corresponding to 16-25 points in the Mini Mental State Examination (MMSE)\n* The cognitive impairment must be supported by the presence of specific levels in cerebrospinal fluid (CSF) of β-Amyloid1-42 (≤1030 pg\u002Fml) and Tau (total and phosphorylated, respectively over 300 pg\u002Fml and 27 pg\u002Fml)\n* MRI scan of the brain with coronal sections showing substance loss (atrophy) of the medial part of the temporal lobe compatible with Alzheimer's disease\n* PET scan of the brain (18F-FDG PET) with decreased regional glucose metabolism in the temporal and parietal regions and PiB (PiB-PET scan) with amyloid plaques in the brain compatible with Alzheimer's disease\n\nExclusion Criteria:\n\n* Patients with active cancer, and in chemo- or radiation therapy\n* Severe cardiovascular disease.\n* Hepatic insufficiency with ASAT\\> 2 x upper limit of normal or renal insufficiency with serum creatinine \\> 200 micromol\u002Fl\n* Severe epilepsy with frequent tonic-clonic (grand mal) seizures\n* Insulin treatment (type 1 diabetes mellitus) and diabetic ketoacidosis\n* Severe chronic disease (e.g., cirrhosis, AIDS, chronic kidney failure)\n* Severe mental illness e.g., schizophrenia, or physical disabilities leading to inability to participate in intervention or tests, or to provide informed consent\n* Evidence for other primary causes of neurodegeneration or dementia, e.g., significant cerebrovascular disease (whose primary cause of dementia was vascular in origin), Lewy Body disease, Parkinson's disease, Fronto-temporal dementia\n* Significant ongoing psychiatric or substance abuse problems.","ALL",{"count":57,"type":20},180,[23],"In the world's high-income countries, Alzheimer's disease and other dementia diseases are currently the second most common cause of death. This is a recent change, as strokes in the form of blood clots or bleedings in the brain previously were the second most common cause of death.\n\nIn Denmark 90,000 live with dementia and life expectancy after dementia diagnosis is 5 to 8 years. Of these, 50,000 have Alzheimer's disease. By 2040 due to a steep increase of the elderly population, the number of people with dementia in Denmark is expected to profoundly increase to 120,000-146,000. This is a concerning forecast which calls for action for several reasons. First and foremost, for the sake of the many thousands of persons who will experience dementia. Every three hours, a Dane dies of dementia. There is currently no cure for Alzheimer's disease and there is a need for the development of an effective therapy. The use of cholinesterase inhibitors, such as donepezil, galantamine and rivastigmine, and the NMDA receptor antagonist memantine, may relieve symptoms, but cannot stop disease progression.\n\nGlucagon-like peptide-1 (GLP-1) receptor agonists (RAs) are among the promising therapies for repurposing as a treatment for Alzheimer's disease. Dementia rate was significantly lower both in type 2 diabetic patients randomized to GLP-1 RAs versus placebo (hazard ratio: 0.47) and in a nationwide Danish registry-based cohort (HR: 0.89) with yearly increased exposure to GLP-1 RAs in a publication on pooled data from three randomized double-blind placebo-controlled trials (15,820 patients) and the cohort (120,054 patients). It is not known whether treatment with GLP-1 RAs may reduce the incidence of dementia in patients without diabetes. There are ongoing studies of whether the GLP-1 RA semaglutide (Rybelsus®), which has a 94% similarity to the naturally occurring human GLP-1 hormone, has a positive effect on early Alzheimer's disease, namely the EVOKE and EVOKE Plus clinical trials.\n\nIn this present placebo-controlled clinical trial, the effect of semaglutide (Rybelsus®) on cognitive impairment in Alzheimer's disease will be investigated. The primary hypothesis is that treatment with semaglutide (Rybelsus®) in combination with other treatments will reduce the progression of the cognitive impairment compared to the control group. In comparison with the EVOKE trials focusing on semaglutide as monotherapy, this present trial will investigate the effect of semaglutide both alone and combined with other treatments.\n\nThe secondary hypothesis is that patients with mild cognitive impairment and Alzheimer's disease have a more frequent incidence of gingivitis and periodontitis, especially with the bacterium Porphyromonas gingivalis producing its toxins in the oral cavity. Recent research has indicated that this bacteria from the mouth and gingiva through the bloodstream can spread to the brain and be a trigger for Alzheimer's disease. Lactobacillus rhamnosus (LGG) has demonstrated to decrease the level of Porphyromonas gingivalis in plaque along with reduction in gingivitis.\n\nFurther hypotheses tested in this trial\n\n* Administration of candesartan to patients with biomarker-confirmed initial-stage Alzheimer's disease will decrease levels of amyloid markers, improve cognitive function, and enhance brain connectivity.\n* Daily multivitamin-mineral, including vitamin D and calcium supplementation, will improve global cognition, episodic memory, and executive functions in older adults.\n* Alzheimer's disease is associated with certain abnormalities of vision and of the structure of the visual system, both of which can precede the development of symptoms of cognitive decline. Hard drusen are yellow deposits under the retina typically made up of lipids and proteins, which may predict retinal pathology, were more commonly found in the temporal region of Alzheimer's disease retinas compared to retinas of normal older patients. Retinal nerve fiber layer thickness will be measured, retinal drusen, retinal hyper-reflective foci, and foveal avascular zone area in patients with treated Alzheimer's disease compared to controls.\n* Gait analysis will be performed and may be particularly sensitive to early symptoms of dementia development.\n* • Biomarkers (p-beta-amyloid, p-tau217 and p-tau181) in cerebrospinal fluid (CSF) will be measured to support suspected Alzheimer's disease.",[61],"Alzheimer Disease (AD)",[63,64,65,66,67],"Alzheimer Disease","Semaglutide","Cognition","Dental care","retinal hyper-reflective foci","2025-08-18",{"date":70,"type":39},"2025-08-22",{"date":72,"type":20},"2026-01-01",{"date":74,"type":20},"2031-09-30",{"name":45,"class":46},{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":55,"minAge":83,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":87,"conditions":88,"keywords":90,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":100,"leadSponsor":102,"locationsCount":4},"100578776","interdisciplinary-interventions-after-mtbi-100578776","NCT06815692","Interdisciplinary Interventions After mTBI","Effect of Interdisciplinary Interventions After Mild Traumatic Brain Injury","Inclusion Criteria:\n\n* Adults who are medically diagnosed with a concussion.\n* Adults with a connection to the labor market.\n* Participants must be able to communicate in Danish and be able to independently participate in the intervention.\n* Participants must be able to transport themsleves to and from SuB facility for their treatment sessions.\n* Rivermead Post-Concussion Symptoms Questionnaire (RPQ) score must be at least 20, indicating a significant severity of symptoms following a concussion.\n\nExclusion Criteria:\n\n* Persons without medically verified concussion.\n* Person where brain injury was found at symptom onset.\n* Persons with significant cognitive dysfunction.\n* Persons who are unable to understand Danish or with communication disorders that hinder test performance.\n* Persons with terminal illness or other progressive disease.\n* Chronic use of opioids.\n* Significant abuse of alcohol or euphoriants or narcotics or other serious illnesses that may affect test results or ability\u002Fpossibility of attendance.","18 Years",{"count":85,"type":20},140,"OBSERVATIONAL","The investigators aim to investigate the impact of interdisciplinary and individually tailored programs for mTBI (concussion) on quality of life and work capacity, both at the conclusion of the program and after 1 and 3 years. The investigators also want to examine whether early intervention is significant by comparing individuals who enter the program between 1 and 3 months post-concussion with those who only start the program more than 9 months post-concussion. Such a study has not been conducted before and can provide valuable insights into long-term effects and the importance of early intervention",[89],"Concussion, Mild",[91,92,93,94,95],"mTBI","employment","weekly working hours","quality of life","Concussion","2025-08-11",{"date":98,"type":39},"2025-08-12",{"date":72,"type":20},{"date":101,"type":20},"2030-12-31",{"name":45,"class":46},{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":111,"sex":55,"minAge":83,"maxAge":4,"enrollmentInfo":112,"targetDuration":4,"studyType":21,"phases":114,"briefSummary":116,"conditions":117,"keywords":122,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":47},"100528465","filter-lenses-for-the-prevention-of-migraine-attacks-100528465","NCT06161129","Filter Lenses for the Prevention of Migraine Attacks","Filter Lenses for the Prevention of Migraine Attacks - Effects of Blue Cut and FL-41 Filter Lenses","COMFORT","Inclusion criteria:\n\n* Adult individuals below the age of 66.\n* Diagnosed with migraine by a neurologist.\n* Able to communicate in Danish\n* Able to voluntarily come to the clinic during an untreated migraine attack.\n* Must have had migraine attacks for more than 1 year.\n\nExclusion criteria:\n\n* Fewer than four migraine attacks per month.\n* Chronic neck pain\n* Chronic headache\n* Chronic use of opioids\n* Presence of a pathological eye condition (in the study, an eye condition is defined as a permanent eye condition that affects the front and back of the eye, such as glaucoma, age-related macular degeneration)\n* Other acquired and congenital retinal diseases must not be present.\n* If there is more than 1 line of deviation on the Snellen chart from habitual correction to best correction, the participant must have a new pair of glasses made at their own expense.",true,{"count":113,"type":20},200,[115],"NA","The purpose is to investigate whether the Blue Cut for Night filter is better at reducing migraine compared to the FL-41 filter or a filter blocking light below 500 nm. A control group will use clear lenses without filter. This is a controlled, randomized and double-blind trial.",[118,119,120,121],"Migraine","Glasses","Headache","Visual Impairment",[118,123,124,125,126],"filter glasses","pain","headache","treatment","2024-12-04",{"date":129,"type":39},"2024-12-09",{"date":131,"type":20},"2026-03-01",{"date":133,"type":20},"2029-02-01",{"name":45,"class":46},""]